Stem Cells ◽  
2010 ◽  
Vol 28 (10) ◽  
pp. 1893-1904 ◽  
Author(s):  
Andrzej Swistowski ◽  
Jun Peng ◽  
Qiuyue Liu ◽  
Prashant Mali ◽  
Mahendra S. Rao ◽  
...  

2010 ◽  
Vol 19 (7) ◽  
pp. 1017-1023 ◽  
Author(s):  
Jingli Cai ◽  
Ming Yang ◽  
Elizabeth Poremsky ◽  
Sarah Kidd ◽  
Jay S. Schneider ◽  
...  

2012 ◽  
Vol 3 (4) ◽  
Author(s):  
Agnete Kirkeby ◽  
Malin Parmar

AbstractThe challenge with controlling the differentiation of human pluripotent cells to generate functional dopaminergic neurons for the treatment of Parkinson’s disease has undergone significant progress in recent years. Here, we summarize the differences between newer and older protocols for generating midbrain dopaminergic neurons from human pluripotent stem cells, and we highlight the importance of following developmental pathways during differentiation. The field has now developed to a point where it is timely to take human pluripotent stem cells one step closer to clinical use, and cell criteria to be fulfilled for such developments are outlined in this review.


2018 ◽  
Vol 4 ◽  
pp. e25423
Author(s):  
Cheng Lin

Grafting of cells in Parkinson's disease (PD) results in a prion-like infection, exhibiting a Lewy body-like pathology, caused by the recipient cells. The transmission mechanism of Lewy bodies is not completely understood. Therefore, a research idea with a novel experimental strategy is proposed to investigate the transmission mechanism of α-synuclein pathology using PD patient-derived human induced pluripotent stem cells (hiPSC) in an in vitro human cellular and molecular PD model and in vivo mouse PD model for dopaminergic neuron transplantation.


Sign in / Sign up

Export Citation Format

Share Document